These stocks, a bargain today, are players to hold on to for the long term.The S&P 500 roared to a record high earlier this year, confirming we are indeed in a bull market, and that's great news for growth stocks. These market environments favor companies that are expanding rapidly and investing to build their businesses. Some of these players have benefited, leading gains in the broader market, but others have been left behind, even though they offer exciting long-term prospects.And these are the players t ...

Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosec ...

BOSTON, April 4, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment, on Thursday, April 11, 2024 in Boston, MA. The conference brings together stakeholders from across the synthetic biology ecosystem and the Ginkgo community, from shareholders and customers to suppliers, academics, and many more. Ginkgo Ferment 2024 Because we have reached in-person capacity, a video livestream of the e ...

The partnership combines Ginkgo's AI/ML and enzyme engineering expertise with Prozomix's wealth of enzyme sequence data to create best-in-class enzymes for API manufacturingNORTHUMBERLAND, England and BOSTON, April 3, 2024 /PRNewswire/ -- Prozomix, a UK-based biotech company focused on novel biocatalyst discovery and manufacturing, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Together, Ginkgo and Prozomix aim ...

Human Natural Killer cell. (National Institute of Allergy and Infectious Diseases Image)The news: Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2) Incubator, has sold its cell therapy platform assets to the Boston biotech company Ginkgo Bioworks. The companies did not disclose the terms of the acquisition. An article by Fierce Biotech noted that Ginkgo’s business development team has snapped up a string of companies and assets in ...

BOSTON, April 2, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor (CAR) and switch receptor libraries. Modulus Therapeutics Ginkgo Bioworks Acquires Modulus Therapeutics’ Cell Therapy Assets to Strengthen Next-Gen CAR Designs Modulus Therapeutics is a cell engineering company focused on the design ...

3 Tips for Sizing Your Penny Stocks Positions in 2024Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires a nuanced approach to position sizing. This strategy ensures that investors can capitalize on opportunities without exposing themselves to undue risk. Three key tips can guide traders in optimizing their investment approach to penny stocks in 2024.[Read More] ...

Ginkgo Bioworks (DNA 1.89%) has a lot going for it. It's a favorite of Cathie Wood's Ark Innovation ETF, it's a popular collaborator in the biopharma sector, and its positioning at the intersection of biotechnology, artificial intelligence (AI), and laboratory robotics means that it's exposed to a lot of exciting and value-enhancing developments.But does that make it a buy, or just another stock getting hyped by the tech-hungry investors of the current bull market? Here's what you need to know.Why this comp ...

LEIDEN, Netherlands , March 13, 2024 /PRNewswire/ -- ProteoNic Biosciences, a leading provider of premium vector technology and services for the production of biologics, today announced a partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. This strategic alliance will grant Ginkgo Bioworks' customers access to ProteoNic's state of the art vector technology in the field of protein production as well as to novel viral vector technology for ...

The TGS program, a leading example of biosecurity infrastructure, operates at a total of nine US locations and leverages voluntary nasal swabs as well as wastewater sampling from international travelers to detect more than 30 pathogens. BOSTON, March 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck, by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of o ...